|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||123.38 - 124.49|
|52 Week Range||111.60 - 124.58|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.20%|
Growth stocks have surged this year in the ongoing post-election rally, but more recently, the value style and related exchange traded funds are beginning to pull ahead. Year-to-date, the iShares Russell ...
The drumbeat of strategists and money managers talking up value over growth continues to get louder, propelled by the looming tax cut. Veteran managers like Templeton's Mark Mobius also are beginning to favor commodity stocks as global growth picks up. BofA ML strategists wrote in a note this week that value factors outdid others last month in the market's reversal, rising 5% while momentum rose 2.7% and growth factors increased 2.3%.
The U.S. stock market is experiencing a “value squeeze” that could last months, according to strategists at J.P. Morgan. It’s when value stocks are deeply out of favor and something happens to trigger a buying rush. Companies that fit that profile now, as it happens, also tend to have value-priced shares.
The ETF fee war continues apace, but by now average industry costs have come down so much that fund sponsors, rather than touting how little they charge compared with their rivals, are encouraging investors ...
Stocks were mixed as Amgen and Celgene hurt biotechs, and ahead of ahead of Amazon and Alphabet's earnings after the close.
In 2017, Mylan (MYL) plans to submit BLAs to the FDA for the approval of biosimilars for trastuzumab, pegfilgrastim, bevacizumab, adalimumab, and insulin glargine.
Dividend strategies have drawn increasing interest from investors around the world as central banks have pursued both quantitative and qualitative easy monetary policies, keeping interest rates at what have been exceptionally low levels since 2008. But this preference isn’t entirely new; it has long been known many investors have a preference for cash dividends. From the perspective of classical financial theory, this behavior is an anomaly.
On August 22, 2017, Baxter International entered into a collaboration with ASPEN (American Society for Parenteral and Enteral Nutrition) and launched SmartPN.
Baxter International (BAX) released its 2Q17 earnings results on July 26, beating the analysts' estimates for both revenues and earnings per share.
In fiscal 1Q18, Medtronic's (MDT) Diabetes Group reported revenues of $449 million, which represents a year-over-year sales decline of ~1%.
Medtronic (MDT) reported its fiscal 1Q18 earnings on August 22, 2017. In this series, we'll look at its stock performance since then.
In 2Q17, Merck’s (MRK) Januvia generated revenues of around $948 million, which reflected an ~11% decline on a year-over-year basis and 13% growth on a quarter-over-quarter basis.
On August 21, 2017, ~59% of the analysts tracking Patterson-UTI Energy rated it as a “buy,” ~37% rated it as a “hold,” and only 4% recommended a “sell.”
In 2Q17, Dentsply Sirona’s (XRAY) Technologies business contributed ~44% to the company’s total revenues and registered sales of ~$439 million.
In 2Q17, Amgen’s (AMGN) Kyprolis generated revenues of ~$211 million, which reflected ~23% growth on a YoY (year-over-year) basis and ~11% growth QoQ (quarter-over-quarter). In 2Q17, Kyprolis witnessed ...